Appili Therapeutics Inc experienced a remarkable surge in its stock price, doubling in value in just one trading session.
In yesterday's trading session, Appili Therapeutics Inc (APLI.TO) saw its stock price soar by an astonishing 100%, closing at CA$0.01. This dramatic increase comes despite the company's ongoing challenges, including its recent application to transfer to the NEX Board due to failure to meet TSX listing requirements.
Investor takeaway: While the surge in Appili's stock price may attract attention, investors should remain cautious given the company's recent operational struggles and strategic shifts.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$661,830
52W high
$0.03
52W low
$0.01
1W change
+0.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI · as of Sep 17, 2026
Wall Street analysts forecast APLI stock price to rise 2900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+2900.0% Upside
Current Price
C$0.01
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
473.3%
Annualized
90-Day Vol
313.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.00 | C$0.00 – C$0.02 |
| 60 trading days | C$0.00 | C$0.00 – C$0.04 |
| 90 trading days | C$0.00 | C$0.00 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The 100% increase in stock price could signal renewed investor interest in Appili's new focus on the biodefence sector. This shift might open doors for future growth opportunities.
Bear case
Even with the impressive one-day gain, the company's move to the NEX Board raises concerns about its financial stability and ability to meet ongoing market demands.
Understanding the Surge
The 100% surge in Appili's stock price can be attributed to a mix of market speculation and potential investor optimism about the company's new direction in biodefence. However, it's crucial to consider the company's financial health and recent strategic decisions.
Advertisement
Challenges Ahead
Despite the impressive gain, Appili's recent application to transfer to the NEX Board highlights significant challenges. Investors should weigh the potential for growth against the backdrop of the company's operational struggles, including its inability to meet TSX listing requirements.
What Investors Should Watch
As Appili Therapeutics moves forward, investors should keep an eye on upcoming announcements regarding its business strategy and operational performance. The company's ability to navigate its challenges while capitalizing on new opportunities will be crucial in determining its long-term viability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
